8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



Date of Report (Date of earliest event reported): April 22, 2005
                                                 (April 22, 2005)



                                  SPECTRX, INC.
             (Exact name of registrant as specified in its charter)







         Delaware                     0-22179                    58-2029543
(State or other jurisdiction      (Commission File             (IRS Employer
     of incorporation)                 Number)              Identification No.)



4955 Avalon Ridge Parkway, Norcross, Georgia                       30071
 (Address of principal executive offices)                        (Zip Code)



Registrant's telephone number, including area code:  (770) 242 - 8723


- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[] Written communications pursuant to Rule 425 under the Securities Act
   (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
   (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
   Act (17 CFR 240.14d-2 (b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
   Act (17 CFR  240.13e-4 (c))


Item 8.01         Other Events.

     On April 22, the registrant announced, among other things, that it expects
to file its Form 10-KSB for the year ended December 31, 2004 with the Securities
and Exchange Commission on or before April 30, 2005, as more fully described in
the press release, a copy of which is filed as Exhibit 99.1 hereto and which
information is incorporated herein by reference.


Item 9.01.        Financial Statements and Exhibits.

(c) Exhibits.

The following exhibit is filed with this report:


Exhibit       Exhibit Description
No.
- --------------------------------------------------------------------------------
99.1          Press Release, dated April 22, 2005



                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.



                                     SPECTRX, INC.




                                     By:    /s/ Mark A. Samuels
                                            ------------------------------------
                                     By:     Mark A. Samuels
                                     Title:  Chairman and CEO
Date:  April 22, 2005

EX-99.1

                                                                    Exhibit 99.1

SpectRx, Inc. Provides Update on Form 10-KSB Filing

    NORCROSS, Ga.--(BUSINESS WIRE)--April 22, 2005--SpectRx, Inc.
(OTCBB: SPRXE) announced it expects to file its Form 10-KSB for the
year ended December 31, 2004, with the Securities and Exchange
Commission on or before April 30, 2005. The delay in filing was
precipitated by a later than normal start to the year-end audit.
    The Company expects to report a loss of approximately $0.28 per
share more than previously reported due to the write off of $3.2
million in intangible assets.
    As a result of the delay in filing the Form 10-KSB, the Company's
stock symbol as been temporarily changed to SPRXE. The Company
anticipates that its stock symbol will revert to SPRX after filing the
Form 10-KSB.

    About SpectRx, Inc.

    SpectRx, Inc. (OTCBB: SPRXE) is a diabetes management company
developing and providing innovative solutions for insulin delivery and
glucose monitoring. SpectRx markets the SimpleChoice(R) line of
innovative diabetes management products, which include insulin pump
disposable supplies. SpectRx also plans to develop a consumer device
for continuous glucose monitoring. The company is commercializing its
non-invasive cervical cancer detection technology through subsidiary
company Guided Therapeutics, Inc, which SpectRx intends to separately
finance with private funds. For more information, visit SpectRx's web
sites at www.spectrx.com, www.mysimplechoice.com and
www.guidedtherapeutics.com.

    "Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995. A number of the matters and subject areas
discussed in this news release that are not historical or current
facts deal with potential future circumstances and developments. The
discussion of such matters and subject areas is qualified by the
inherent risks and uncertainties surrounding future expectations
generally and also may materially differ from SpectRx's actual future
experience involving any of or more of such matters and subject areas.
Such risks and uncertainties include: the early stage of products in
development, the uncertainty of market acceptance of products, the
uncertainty of development or effectiveness of distribution channels,
the intense competition in the medical device industry, the
uncertainty of capital to develop products, the uncertainty of
regulatory approval of products, dependence on licensed intellectual
property, as well as those that are more fully described from time to
time in SpectRx's reports under the heading "Risk Factors" filed with
the SEC, including SpectRx's Annual Report on Form 10-K for the fiscal
year ended December 31, 2003 and subsequent quarterly reports.

    CONTACT: SpectRx, Inc., Norcross
             Bill Wells, 770-242-8723